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Introduction. In the light of modern ideas, the comorbid pathology of a 
patient is determined as a combination of two and/or more chronic diseases 
which are interconnected pathogenically and contemporaneously regardless of 
activity of each of them [5, 12]. From the clinical point of view, comorbidity 
leads to the change of a regular clinical picture of diseases, aggravates their 
course, contributes to development of complications and is an independent risk 
factor of the lethal outcome [13]. Chronic obstructive pulmonary disease 
(COPD) and cardiovascular diseases, first of all, essential hypertension (EHT) 
are leaders both in the structure of morbidity and mortality among pathology of 
internal organs [2, 4, 6], especially in cases of their combination [9]. Nowadays, 
the change of the functional state of endothelium in the patients with COPD and 
EHT is considered as one of the key mechanisms in pathogenesis of these 
diseases [7, 11, 8, 10] and is a possible connecting link between 
bronchopulmonary pathology and cardiovascular diseases [3]. The foregoing 
and also a frequent combination of COPD and EHT in the clinic of internal 
diseases [1] were a precondition for carrying out this study.  The aim of the 
research was to study the peculiarities and the possible changes of the functional 
state of endothelium in the patients with COPD in conditions of its comorbidity 
with EHT. 
Materials and methods. The group of the examined individuals included 64 
patients with COPD of the II stage (females-22, males-44, mean age-54,8±2,5 
years), among whom 32 patients had the comorbid EHT of the II degree; the 
patients’ status was the medicamentous compensation. All the patients were 
divided into 2 groups: the main group (COPD combined with EHT) and the 
comparative group (COPD). The control group included 15 practically healthy 
individuals. They and the examined patients were of the same sex and age. 
The diameter of the right brachial artery (DRBA, mm) in transverse and 
longitudinal planes (ultrasound scanner «Aloka 5000» Pro Sound (Japan) was 
taken into account for analysis of the endothelium’s vasoregulating function. 
Endothelium-dependent vasodilatation (EDVD) was determined within 90 sec 
after a 5-minute compression of a shoulder by pressure 300 mm Hg by means of 
calculating the percentage of the change of an arterial diameter in comparison 
with the initial one. Endothelium-independent vasodilatation (EIVD) was 
determined as a maximal value of the percentage of arterial dilatation during 5 
minutes after a sublingual intake of 0.5 mg nitroglycerin at once-a-minute 
registration. 
The total content of the stable metabolites of nitrogen oxide (NOХ) was 
determined in blood serum by the spectrophotometric method by means of the 
assay kit «Тоtal NO» («RL-system», USA) in accordance with the kit 
instructions; the determination of a level of endothelin-1 (ET-1) was carried out 
by the immunoenzymatic method by means of the assay kit BIG Endothelin-1 
(HUMAN), Peninsula Laboratories inc., Division of Bachem. 
Mathematical processing of the results was carried out by means of 
variation statistics methods using application programs package Statistika 6.0.  
Results. An increase of DRBA in the patients of the main group in 
comparison with the healthy individuals (in 1.53 times; р<0.001) and the 
increasing tendency in comparison with the comparative group was revealed. 
The indices of EDVD and EIVD were 10.2±0.4% and 7.0±0.2%, accordingly. 
They were significantly low among the all examined (р<0.001). Besides, they 
were, accordingly, 1.34 and 1.29 times as little as among the patients of the 
comparative group. At the same time, the NOХ index in the patients of the main 
group (16.2±1.3 mcmol/l) was 2.24 times as low as among the patients of  the 
control group and 1.64 times as low as among the patients of the comparative 
group (р<0.001 in both cases). The ET-1 level was the highest among the 
patients of the main group (5.2±0.1 pmol/l); it was  1.63 times  as  high as 
among the patients of the control group and 1.3 times as much high as among 
the patients of the comparative group(р<0.001 in both cases). The correlation 
relationship between EDVD, EIVD and NOХ was established in the patients 
with COPD and EHT (accordingly, r= 0.36 and r= 0.44; p<0.05). A negative 
correlation relationship between indices NOХ and DRBA (r= -0.49; p<0.05) was 
established too. 
Conclusion. The change of the endothelial function, diagnosed in the 
patients with COPD, is the most significant one in case of its combination with 
EHT. A decrease of vasorelaxation indices in such patients is accompanied by 
an increase of ET-1 content and caused by the decrease of the NOХ content. It is 
reflected by the presence of the correlation relationship between DRBA, EDVD, 
EIVD and NOХ.  
Prospects for the further research. The established peculiarities of the 
change of the endothelial function in the patients with COPD and comorbid 
EHT are a prerequisite for the study of their possible interconnection with 
hemostasis factors and for the specification of their role in genesis of 
atherothrombosis.  
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